Clinton Group’s Array Biopharma Inc ARRY Stock Holding History

Clinton Group’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-19,968	Closed	-$144K	–	888
2015 Q2	$144K	Buy	+19,968	New	+$147K	0.02%	551

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Clinton Group's ARRY Position: Q3 2015 in Review

Clinton Group sold out of Array Biopharma Inc (ARRY) in Q3 2015, closing a stake of 19,968 shares — an estimated $144K sold.

Clinton Group first reported a position in ARRY in Q2 2015 and held it in 1 quarter. The position peaked at $144K in Q2 2015. 157 funds tracked by Wall St. Rank hold ARRY as of Q3 2015.

Clinton Group reported no remaining Array Biopharma Inc position as of Q3 2015 after selling out during the quarter.
Clinton Group sold 19,968 Array Biopharma Inc shares in Q3 2015, an estimated $144K.
Clinton Group first reported a position in Array Biopharma Inc in Q2 2015 and held it in 1 quarter.
Clinton Group's Array Biopharma Inc position peaked at $144K in Q2 2015.
157 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2015.

Based on Clinton Group's 13F filing for Q3 2015, filed 13 Nov 2015.